Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating constipation containing l-arabinose and its application method

A kind of arabinose, a technology for treating constipation, applied in the field of biomedicine, can solve problems such as unsuitable for long-term use, drug dependence, weak effect, etc., and achieve the effect of increasing intestinal water content, promoting peristalsis, and preventing rapid loss

Active Publication Date: 2021-07-20
唐传生物科技(厦门)有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main disadvantages of this kind of medicine are poor taste, weak effect, and long-term use will form drug dependence, so it is not suitable for long-term use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating constipation containing l-arabinose and its application method
  • Pharmaceutical composition for treating constipation containing l-arabinose and its application method
  • Pharmaceutical composition for treating constipation containing l-arabinose and its application method

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0026] The impact experiment of pharmaceutical composition on constipation mouse defecation is as follows:

[0027] Take 110 clean-grade mice (experimental mice were purchased from the Experimental Animal Center of Xiamen University, license number SYXK (Fujian) 2018-0010), weighing 20±2g, male and female, and randomly divided into 11 groups, 10 in each group. The specific groups are Example 1, Example 2, Example 3, Example 4, normal control group, model control group, comparative example 1, comparative example 2, comparative example 3, comparative example 4, and comparative example 5.

[0028] Among them, except for the normal control group, the other 10 groups used the compound diphenoxylate to establish the constipation mouse model, and the dosage of the compound diphenoxylate was 10 mg / kg.

[0029] 12 hours before the start of the test, food and water were not allowed. The experiment was administered according to Table 1. The timing was started after the gavage. Each mouse...

experiment example 2

[0050] The pharmaceutical composition of the present invention is made into 3g / bag powder (99.9wt% of L-arabinose and 0.1wt% of gamma-polyglutamic acid) for trial use by people with constipation. A total of 42 cases of trial people are used for voluntary trial of constipation. patient.

[0051] Table 4. Basic information of trial patients (age range 27-65 years old)

[0052]

[0053] The classification criteria for the degree of constipation in patients with constipation are as follows:

[0054] Mild constipation: defecate every other day, the stool is dry; defecation is laborious;

[0055] Moderate constipation: generally have a bowel movement every 2-3 days, the stool is dry, and occasionally blood is present during defecation;

[0056] Severe constipation: usually only once a week for 4-5 days or even a week, and the defecation volume is small and the defecation process is painful, often need to rely on lubricants such as Kaisailu to complete defecation;

[0057] expe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides a pharmaceutical composition containing L-arabinose for treating constipation and an application method thereof. The pharmaceutical composition is composed of L-arabinose and γ-polyglutamic acid, wherein, L-arabinose and γ-polyglutamic acid The weight ratio of glutamic acid is 90‑100:0.01‑10. After the L-arabinose in the pharmaceutical composition of the present invention enters the large intestine, a concentration difference is formed, and under the action of osmotic pressure, the water around the intestine is sucked into the large intestine to increase the water content of the intestine. At the same time, γ‑polyglutamic acid plays the role of locking water, softening the stool, increasing the volume of the intestinal cavity, preventing the rapid loss of water entering the intestinal tract, prolonging the residence time of water in the intestinal tract, prolonging the contact time between water and feces, and fully softening Stool, increase content, promote peristalsis. The combination of the two can achieve the effect of treating constipation by increasing the water content of the feces, softening the feces, and promoting intestinal peristalsis to discharge the feces, and the effect is remarkable.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a pharmaceutical composition containing L-arabinose for treating constipation and an application method thereof. Background technique [0002] Constipation is a common intestinal disease, which refers to a decrease in the number of bowel movements, and at the same time difficult bowel movements and dry stools. Normal people defecate 1-2 times a day or once every 1-2 days. Many patients with constipation defecate less than 3 times a week. In severe cases, they only defecate once every 2-4 weeks, and the defecation is laborious and hard. , the amount is small; some patients can defecate for more than 30 minutes, or defecate many times a day, but the discharge is difficult, the feces are hard and hard like sheep feces, and the number is small. Constipation is a common symptom of the elderly, and about 1 / 3 of the elderly suffer from constipation, which seriously affects the qual...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7004A61K31/785A61P1/10
CPCA61K31/7004A61K31/785A61P1/10A61K2300/00
Inventor 林卫军石国良王羽娟陈旭萧舜之陈建军
Owner 唐传生物科技(厦门)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com